| Literature DB >> 33540837 |
Raphael Mohr1, Burcin Özdirik1, Joeri Lambrecht1, Münevver Demir1, Johannes Eschrich1, Lukas Geisler1, Teresa Hellberg1, Sven H Loosen2, Tom Luedde2, Frank Tacke1, Linda Hammerich1, Christoph Roderburg1,2.
Abstract
In almost all cases, hepatocellular carcinoma (HCC) develops as the endpoint of a sequence that starts with chronic liver injury, progresses to liver cirrhosis, and finally, over years and decades, results in liver cancer. Recently, the role of non-coding RNA such as microRNA (miRNA) has been demonstrated in the context of chronic liver diseases and HCC. Moreover, data from a phase II trial suggested a potential role of microRNAs as therapeutics in hepatitis-C-virus infection, representing a significant risk factor for development of liver cirrhosis and HCC. Despite progress in the clinical management of chronic liver diseases, pharmacological treatment options for patients with liver cirrhosis and/or advanced HCC are still limited. With their potential to regulate whole networks of genes, miRNA might be used as novel therapeutics in these patients but could also serve as biomarkers for improved patient stratification. In this review, we discuss available data on the role of miRNA in the transition from liver cirrhosis to HCC. We highlight opportunities for clinical translation and discuss open issues applicable to future developments.Entities:
Keywords: biomarker; hepatocellular carcinoma; miRNA; translational
Mesh：
Substances：
Year: 2021 PMID： 33540837 PMCID： PMC7867354 DOI： 10.3390/ijms22031492
Source DB: PubMed Journal: Int J Mol Sci ISSN： 1422-0067 Impact factor: 5.923